Table 3 Correlation analysis of risk factors with the prognosis of patients with drug eruption.
From: Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China
Risk factor | Drug eruption group (n = 134) | P value | ||
---|---|---|---|---|
Cured/improved cases (n = 124) | Death cases (n = 10) | |||
Sex | Male | 83 (93.3) | 6 (6.7) | 0.679 |
Female | 41 (91.1) | 4 (8.9) | ||
Age | ≤50 | 98 (92.5) | 8 (7.5) | 0.942 |
>50 | 26 (92.9) | 2 (7.1) | ||
Allergic history | Yes | 16 (76.2) | 5 (23.8) | 0.008a |
No | 108 (95.6) | 5 (4.4) | ||
Opportunistic infection | Yes | 72 (77.8) | 10 (12.2) | 0.009a |
No | 52 (100.0) | 0 (0.0) | ||
HAART | Yes | 78 (95.1) | 4 (4.9) | 0.153 |
No | 46 (88.5) | 6 (11.5) | ||
Sensitization route | Intravenous | 38 (88.4) | 5 (11.6) | 0.363 |
Oral | 86 (94.5) | 5 (5.5) | ||
Fever | Yes | 43 (93.0) | 4 (7.0) | 1.000 |
No | 81 (92.2) | 6 (7.8) | ||
Lymphadenectasis | Yes | 7 (87.5) | 1 (12.5) | 0.472b |
No | 117 (92.9) | 9 (7.1) | ||
Viral load | Median ± IRc | 1950.00 ± 288700.00 | 440000.00 ± 1917225.00 | 0.008a |
CD4+ T cell count | Median ± IR | 157.50 ± 219.25 | 41.50 ± 122.25 | 0.021a |
t-Bil | Median ± IR | 8.70 ± 8.70 | 12.30 ± 10.40 | 0.400 |
AST | Median ± IR | 45.00 ± 69.25 | 44.00 ± 32.00 | 1.000 |
ALT | Median ± IR | 42.50 ± 87.00 | 39.00 ± 86.25 | 0.684 |
ALB | Median ± IR | 36.15 ± 6.35 | 31.35 ± 13.00 | 0.002a |
GLB | Median ± IR | 29.95 ± 8.33 | 29.05 ± 8.60 | 0.694 |
CREA | Median ± IR | 63.00 ± 20.00 | 59.80 ± 40.50 | 0.531 |
BUN | Median ± IR | 3.60 ± 2.25 | 5.75 ± 4.37 | 0.192 |
WBC | Median ± IR | 3.97 ± 2.53 | 3.15 ± 1.83 | 0.041a |
NEU | Median ± IR | 2.42 ± 2.10 | 1.95 ± 1.49 | 0.207 |
LYM | Median ± IR | 1.00 ± 0.85 | 0.80 ± 0.47 | 0.109 |
RBC | Mean ± SD | 4.00 ± 0.67 | 3.31 ± 0.60 | 0.002a |
Hb | Mean ± SD | 121.54 ± 18.25 | 98.10 ± 18.53 | <0.001a |
PLT | Mean ± SD | 166.62 ± 74.60 | 148.00 ± 72.21 | 0.448 |
EOS | Median ± IR | 0.10 ± 0.22 | 0.11 ± 0.45 | 0.760 |